wiry

How can you separate "marketing fluff" from a true "value proposition" in this world of TMI (too much information)? This is not an easy question to answer, and we don't claim we have some magic crystal ball. We do, however, believe that our patent search tools are designed in such a way as to provide objective and transparent results to allow you to Discover, Measure, Compare, and Connect business opportunities. Many patent analytics tools are available. So what makes us different? Simple. We take the complexities and reduce them to meaningful visualizations. We take the complex legalese and simplify it to interpretable business intelligence to better understand the analytics of it.

You need IP intelligence to meet corporate objectives related to your business function. IP Street is driving the innovation economy and managing IP assets with know-how and confidence. IP Street.com takes a patent search to a whole new level by helping you better understand patent analytics, patent duration, patent value, patent infringement and the steps needed to patent an idea or patent an invention.

Myopia is generally what happens when unprecedented opportunities are placed before them. Those in the know generally do better than those in the worry. Consider Cetus, a startup biotech with a focus on a liver drug. The FDA delayed the approval of the drug, and a major funding crisis ensued. Chiron offered to take over the liabilities contingent on the sale of two patents (# 4,683,202 and # 4,683,195) to a third party, Roche Molecule for $300M (in 1993). This sale was stalled because DuPont challenged the validity of the patents, based on the formal claims written by the inventor (not a patent attorney), Kary Mullis. In the end, the soap opera turned out well for the investors with weak constitutions. For $300M, they sold the two patents to Roche, turned the company over to Chiron, and walked away. Kary Mullis won the Nobel prize for his invention embedded in these two patents, known as polymerase chain reaction (PCR) which allows DNA to be cloned. Over 4000 patents in biotech cite these original two patents. In our estimation, $300M represents "pennies on the dollar" valuation of these patents. The shareholders got a payday, and left the game. Roche on the other hand is thriving based on its intangible assets. Let IPstreet.com assist you.